International Centre for Cardiothoracic and Vascular Diseases, Department of Biochemistry, Dr K.M Cherian Heart Foundation (A Unit of Frontier LifeLine Pvt Ltd), R-30C, Ambattur Industrial Estate Road, Mogappair, Chennai 600 101, India.
Heart Lung Circ. 2010 Nov;19(11):660-4. doi: 10.1016/j.hlc.2010.06.665. Epub 2010 Aug 1.
Diagnosis of myocardial ischaemia at an early stage in the emergency department is often difficult. A recently proposed biomarker, heart fatty acid binding protein (H-FABP) has been found to appear in the circulation superior to that of cardiac troponins in the early hours of acute coronary syndrome. We proposed to evaluate the levels of H-FABP and ascertain its utility as an early biomarker for acute coronary syndrome (ACS).
The present study was carried out in 485 subjects, of whom 297 were diagnosed as patients with ACS, 89 were diagnosed as non-cardiac chest pain (NCCP) and 99 people served as healthy controls. H-FABP levels were measured in comparison with standard markers such as troponin I and CK-MB in all subjects enrolled in the study. The levels of H-FABP were significantly raised in patients when compared to controls and NCCP (P<0.001). Receiver Operator Characteristic Curve (ROC) analysis showed H-FABP to be a good discriminator between patients with ischaemic heart disease and patients without ischaemic heart disease. The area under the curve was found to be 0.965 with 95% CI (0.945-0.979). The cut-off value above which H-FABP can be considered positive was found to be 17.7ng/ml.
H-FABP is a promising biomarker for the early detection of patients with acute coronary syndrome.
在急诊科早期诊断心肌缺血通常很困难。最近提出的一种生物标志物，心脏脂肪酸结合蛋白（H-FABP）在急性冠状动脉综合征发生后的早期出现在循环中，其出现时间优于心肌肌钙蛋白。我们提出评估 H-FABP 的水平，并确定其作为急性冠状动脉综合征（ACS）的早期生物标志物的效用。
本研究在 485 名受试者中进行，其中 297 名被诊断为 ACS 患者，89 名被诊断为非心源性胸痛（NCCP），99 人作为健康对照。在所有入组研究的受试者中，与肌钙蛋白 I 和 CK-MB 等标准标志物一起测量 H-FABP 水平。与对照组和 NCCP 相比，患者的 H-FABP 水平显着升高（P<0.001）。受试者工作特征曲线（ROC）分析表明，H-FABP 可以很好地区分缺血性心脏病患者和无缺血性心脏病患者。曲线下面积为 0.965，95%CI（0.945-0.979）。发现 H-FABP 可被认为是阳性的截断值为 17.7ng/ml。
H-FABP 是一种有前途的生物标志物，可用于早期检测急性冠状动脉综合征患者。
